Disulfiram and Cisplatin in Refractory TGCTs. - Trial NCT03950830
Access comprehensive clinical trial information for NCT03950830 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National Cancer Institute, Slovakia
Timeline & Enrollment
Phase 2
May 14, 2019
Dec 31, 2022
Primary Outcome
Overall response rate
Summary
Non-randomized, open-label, single center trial to assess efficacy (as measured by overall
 response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple
 relapsed/refractory germ cell tumors (GCTs).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03950830
Non-Device Trial